세계 신경과 시장 규모는 2024년 673억 달러에서 예측 기간 동안 CAGR 7.1%로 추이하고 2029년에는 948억 달러에 달할 것으로 예측되고 있습니다.
다발성 경화증 부문은 2024년 225억 달러에서 CAGR 3.9%로 추이해 2029년에는 272억 달러에 이를 것으로 예측됩니다. 뇌종양 부문은 2024년 29억 달러에서 CAGR 12.6%로 추이해 2029년에는 53억 달러에 이를 것으로 예측됩니다.
본 보고서에서는 세계 신경과 시장을 조사했으며, 시장 개요, 시장 영향인자 및 시장기회 분석, 법규제 환경, 파이프라인 동향, 시장 규모 추이와 예측, 각종 구분, 지역별 상세 분석, 경쟁 구도, 주요기업 프로파일 등을 정리했습니다.
목차
제1장 주요 요약
제2장 시장 개요
- 개요
- Porter's Five Forces 분석
- 신경과에서의 의료 코드화와 청구의 과제
- 단계적 치료
- Medicare 삭감
- 코딩 오류
- 모디파이어의 사용
- 문서화
- 보상 범위와 사전 승인
- 컴플라이언스 및 감사
- 상환율과 거부
- 의사의 지불의 과제
- 평가 및 관리(E/M) - 적절한 수준의 케어를 청구
- 계약 협상
제3장 시장 역학
- 시장 역학
- 시장 성장 촉진요인
- 신경질환을 가진 노인 인구 증가
- 신경질환의 세계 발생률 증가
- 정부와 NGO에 의한 의식 계발 활동
- 신경과에서의 조사 이니셔티브
- 시장 성장 억제요인
- 브랜드 의약품의 특허 만료과 제네릭 의약품의 출현
- 부작용
- 의약품 개발의 고비용성
제4장 새로운 동향과 파이프라인 분석
- 새로운 동향
- 신경 질환에 있어서의 정밀의료
- 신경 질환에 대한 유전자 치료
- 신경 변성과 줄기 세포 치료
- 신경과의 나노 기술
- 가상현실과 디지털 치료
- 총론
- 파이프라인 분석
제5장 규제 상황
- 개요
- 학제 간 가치 이야기
- 고품질 환자보고 결과 데이터
- EU와 미국의 신법의 영향
- 총론
제6장 시장 세분화 분석
- 부문별 내역
- 시장 분석 : 적응증별
- 파킨슨병
- 알츠하이머병
- 정신병성 장애
- 간질장애
- 자폐증 스펙트럼 장애
- 뇌종양
- 다발성 경화증
- 기타
- 지리적 내역
- 시장 분석 : 지역별
- 북미
- 유럽
- 아시아태평양
- 기타 지역
제7장 경쟁 정보
- 파킨슨병 치료제의 기업 점유율 분석
- 알츠하이머병 치료제의 기업 점유율 분석
- 항정신병약의 기업 점유율 분석
- 항 간질 치료제의 기업 점유율 분석
- 자폐증 스펙트럼 장애 치료제의 기업 점유율 분석
- 뇌종양 치료제의 기업 점유율 분석
- 다발성 경화증 치료제의 기업 점유율 분석
제8장 부록
- 조사 방법
- 출처
- 약어
- 기업 프로파일
- ABBVIE INC.
- ALPHA COGNITION
- BIOGEN
- BOEHRINGER INGELHEIM INTERNATIONAL GMBH
- BRISTOL-MYERS SQUIBB CO.
- EISAI CO. LTD.
- F. HOFFMANN-LA ROCHE LTD.
- H. LUNDBECK A/S
- LILLY
- MERCK & CO. INC.
- NOVARTIS AG
- OTSUKA HOLDINGS CO. LTD.
- SANOFI
- TEVA PHARMACEUTICAL INDUSTRIES LTD.
- UCB SA
JHS
The global market for neurology is estimated to increase from $67.3 billion in 2024 to reach $94.8 billion by 2029, at a compound annual growth rate (CAGR) of 7.1% from 2024 through 2029.
The multiple sclerosis market for neurology is estimated to increase from $22.5 billion in 2024 to reach $27.2 billion by 2029, at a CAGR of 3.9% from 2024 through 2029.
The brain tumor market for neurology is estimated to increase from $2.9 billion in 2024 to reach $5.3 billion by 2029, at a CAGR of 12.6% from 2024 through 2029.
Report Scope
This report includes a market analysis of the therapeutics used to treat neurological conditions. The study outlines the market potential for neurology medications for both now and in the future. It also provides a thorough examination of the market's drivers, constraints, and pipeline medications, as well as the competitive landscape, laws, epidemiology of neurological disorders, mergers and acquisitions. Market forecasts through 2029 are also covered in the report.
The report breaks down neurology market shares according to various disease indications. Parkinson's disease, Alzheimer's disease, psychotic disorder, epileptic disorder, autism disorder, multiple sclerosis, brain tumor, and other diseases are the neurological disorders that make up the market segmentation. Therapeutics and regional analysis are covered in each disease segment.
Anti-Parkinson's medications are covered in the Parkinson's disease market. The market is divided into different drug classes such as dopaminergic, enzyme inhibitors, dopamine agonists and other anti-Parkinson's drugs based on drug class. Anti-Alzheimer medications are part of the Alzheimer's disease market, which is divided into segments according to respective mechanisms of action. The market is divided into two segments based on drug class: NMDA antagonists and AChE inhibitors. Antipsychotic medications are part of the market for psychotic diseases. The market is divided into different drug classes, including D2 partial agonists, D2/5HT2A antagonists, and D2 antagonists.
Anti-epileptic medications are included in the market for epileptic diseases. The market is divided into three segments based on drug class: first-generation, second-generation and third-generation. Autism spectrum disorder drugs are included in the market. Based on information on labels, the market is divided into drug categories: off-label pharmaceuticals and pharmaceuticals with an ASD label. Brain tumor treatments are included in the market for brain tumors. The market is divided into different types of therapy, such as targeted therapy and chemotherapy.
In order to provide an in-depth understanding of the market, profiles of market participants, competitive landscape, key competitors and respective market share are also part of this report. By geographical region, the market in this report is divided into four regions: North America, Europe, Asia-Pacific, and Rest of the World (RoW). For market estimates, data has been provided for 2023 as the base year, with forecasts for 2024 through 2029.
Report Includes
- 52 data tables and 59 additional tables
- Analyses of the global market trends for neurology therapeutics, with market revenue data (sales figures) for 2022, estimates for 2023, forecasts for 2024, and projected CAGRs through 2029
- Estimates of the market size and revenue growth prospects, along with a market share analysis by type of disorder, drug classification, mechanism of action, label information, end user and region
- Facts and figures pertaining to key market dynamics, technology advances, pipeline drugs, regulations, and the impact of macroeconomic factors
- Insights derived from the Porter's Five Forces model, as well as global supply chain and PESTLE analyses
- Pipeline analysis covering ongoing clinical trials and promising forthcoming neuroscience therapies in late stage
- Discussion of therapeutics used for treatment of neurological disorders, along with coverage of novel pipeline drugs, patent expiries of blockbuster drugs and new drug approvals
- A patent analysis, including key granted and published patents
- Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
- Company profiles of major players within the industry, including F. Hoffmann-La Roche Ltd., Novartis AG, UCB S.A, and Otsuka Holdings Co. Ltd.
Table of Contents
Chapter 1 Executive Summary
- Market Outlook
- Scope of Report
- Market Summary
Chapter 2 Market Overview
- Overview
- Porter's Five Forces Analysis
- Potential for New Entrants (Low to Moderate)
- Bargaining Power of Suppliers (Moderate to High)
- Bargaining Power of Buyers (Moderate)
- Threat of Substitute Products or Services (Moderate to High)
- Industry Rivalry (High)
- Medical Coding and Billing Challenges in Neurology
- Step Therapy
- Medicare Cuts
- Coding errors
- Use of Modifiers
- Documentation
- Coverage and Prior Authorization
- Compliance and Audits
- Reimbursement Rate and Denials
- Physician Payment Challenges
- Evaluation and Management (E/M) - Bill the Correct Level of Care
- Negotiating Contracts
Chapter 3 Market Dynamics
- Market Dynamics
- Market Drivers
- Growing Geriatric Population with Neurological Disorders
- Increasing Global Incidence of Neurological Disorders
- Government and NGO Initiatives in Creating Awareness
- Research Initiatives in Neurology
- Market Restraints
- Patent Expirations of Branded Drugs and Emergence of Generics
- Adverse Side Effects
- High Cost of Drug Development
Chapter 4 Emerging Trends and Pipeline Analysis
- Emerging Trends
- Precision Medicine in Neurological Disorders
- Gene Therapy for Neurological Disorders
- Neurodegeneration and Stem Cell Therapy
- Nanotechnology in Neuroscience
- Virtual Reality and Digital Therapeutics
- Conclusion
- Pipeline Analysis
Chapter 5 Regulatory Landscape
- Overview
- Cross-Disciplinary Value Story
- High-Quality Patient-Reported Outcome Data
- Impact of New EU and the U.S. Legislation
- Conclusion
Chapter 6 Market Segmentation Analysis
- Segmental Breakdown
- Market Analysis by Disease Indication
- Parkinson's Disease
- Alzheimer's Disease
- Psychotic Disorders
- Epileptic Disorder
- Autism Spectrum Disorder
- Brain Tumor
- Multiple Sclerosis
- Others
- Geographic Breakdown
- Market Analysis by Region
- North America
- Europe
- Asia-Pacific
- Rest of the World
Chapter 7 Competitive Intelligence
- Company Share Analysis of Anti-Parkinson's Drugs
- Company Share Analysis of Alzheimer's Disease Drugs
- Company Share Analysis of Antipsychotic Drugs
- Company Share Analysis of Anti-Epileptic Drugs
- Company Share Analysis of ASD Therapeutics
- Company Share Analysis of Brain Tumor Therapeutics
- Company Share Analysis of Multiple Sclerosis Therapeutics
Chapter 8 Appendix
- Methodology
- Sources
- Abbreviations
- Company Profiles
- ABBVIE INC.
- ALPHA COGNITION
- BIOGEN
- BOEHRINGER INGELHEIM INTERNATIONAL GMBH
- BRISTOL-MYERS SQUIBB CO.
- EISAI CO. LTD.
- F. HOFFMANN-LA ROCHE LTD.
- H. LUNDBECK A/S
- LILLY
- MERCK & CO. INC.
- NOVARTIS AG
- OTSUKA HOLDINGS CO. LTD.
- SANOFI
- TEVA PHARMACEUTICAL INDUSTRIES LTD.
- UCB S.A.
